NSCLC Stage IV
Conditions
Keywords
NSCLC, Oligoprogressive, Immune checkpoint inhibitors, SBRT
Brief summary
The treatment modality with immunotherapy has been the first-line standard treatment for advanced NSCLC. But more than 2/3 patients still develop acquired drug resistance within 5 years of immunotherapy, and more than 1/2 patients are oligoprogressive. Stereotactic body radiation therapy (SBRT) plays a growing role in the management of oligometastatic disease. This study aims to evaluate the efficacy and safety of SBRT for oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors.
Interventions
RADIATIONSBRT
Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age at least 18 years; * ECOG PS 0-1; * Patients with pathologically confirmed stage IV NSCLC by tumor biopsy and/or fine-needle aspiration （AJCC the 8th Edition）; * Stable Disease for at least 6 months after first line immunotherapy; * Oligoprogressive disease in 5 or fewer lesions and 3 or fewer organs; * All oligopreogressive lesion ≤ 5cm, and intracranial lesion ≤3cm or 30cc; * Progressive disease would be amenable to SBRT and without indications for palliative radiotherapy in the opinion of the investigator; * Patients with a history of radiotherapy are eligible if radiotherapy administered more than 4 weeks before study entry; * Adequate organ function prior to enrollment: Adequate bone marrow function: white blood cell (WBC) count ≥ 3.0 \* 10 \^ 9/L or neutrophil count ≥ 1.5 \* 10 \^ 9/L, platelet count ≥ 100 \* 10 \^ 9/L and hemoglobin ≥90g/L,; Adequate hepatic function: total bilirubin, urea nitrogen and serum creatinine≤ 1.5 x upper limit of normal (ULN). Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.0 ULN; * Life expectancy of more than 3 months; * Ability to understand and willingness to provide the informed consent and signed informed consent for the use of fresh tumor biopsies before and during the treatment; * Women of childbearing age and men must agree to use effective contraception during the trial.
Exclusion criteria
* History of another malignancy or concurrent malignancy (except for cured non-melanoma skin cancer, low-risk prostate cancer, T1/T2 glottic cancer, stage 0 or I breast cancer, non-invasive bladder cancer, cervical cancer in situ); * Positive for driver genes including EGFR, ALK, and ROS-1; * Mixed small cell with non-small cell lung cancer histology; * Malignant pleural or ascites; * Patients with brain metastasis require intracranial decompression; * Symptoms of spinal cord compression; * Severe autoimmune disease: inflammatory bowel disease (including Crohn's disease and ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, Wegener's granulomatosis and related vasculitides; * Symptomatic interstitial lung disease or clinically active infectious/non-infectious pneumonitis. * History of another malignancy or concurrent malignancy; * Active infection, congestive heart failure, or any evidence of myocardial infarction, unstable angina pectoris or cardiac arrhythmia within 6 months prior to enrollment; * The patient is pregnant (confirmed by serum b-HCG if applicable) or is breastfeeding; * Mental disorders, drug abuse, and social condition that may negatively impact compliance in the investigator's opinion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progress free survival | two years | PFS was defined from the date of enrollment to the date of disease progression |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | two years | OS was defined from the date of enrollment until death by any cause or last follow-up. |
| Grade 3 or higher toxicity | two years | Treatment-related grade 3 or higher adverse events according to CTCAE 5.0. |
| Time to new metastasis | 2 years | Time to new metastasis was defined from the date of enrollment to the date of new lesion progression. |
Countries
China
Contacts
Primary ContactXiaojing Lai
Backup ContactMin Fang, MD
Outcome results
None listed